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Background and aims. In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption
in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years.
Methods. GLP-2, 400micrograms, s.c.,TID, were oﬀered, to eleven SBS patients keeping parenteral support constant. 72-hour
nutritionalbalancestudieswereperformedatbaseline,weeks13,26,52duringtwoyearsintermittedbyan8-weekwashoutperiod.
In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by
DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR,
lungfunction, exercise test) were measured. Results. GLP-2 compliance was >93%. Three of eleven patients did not complete the
study. In the remaining 8patients, GLP-2 signiﬁcantly reduced the fecal wet weight from approximately 3.0 to approximately
2.0kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and
urinary weight constant. Renal function improved. No signiﬁcant changes were demonstrated in energy intake or absorption, and
GLP-2 did not signiﬁcantly aﬀect mucosal morphology, body composition, bone mineral density or muscle function. Conclusions.
GLP-2 treatment reduces fecal weight by approximately 1000g/d and enables SBS patients to maintain their intestinal ﬂuid and
electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.
Copyright © 2009 P. B. Jeppesen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
GLP-2 is cosecreted with GLP-1 from the enteroendocrine L
cells following nutrient ingestion [1]. In animal and human
studies, GLP-2 decreases gastric acid secretion [2], inhibits
antral gastric emptying [3, 4] and upregulates intestinal
blood-ﬂow [5]. In addition, GLP-2 has been demonstrated
to have trophic eﬀects on the intestinal mucosa [6–9]
and positive eﬀects on the absorptive function [10–12].
Furthermore, GLP-2 decreases bone resorption [13].
Theoretically, treatment with GLP-2 could reduce the
rapid gastric emptying and hypersecretion and increase
the intestinal absorption in short bowel syndrome (SBS)
patients. In addition, GLP-2 could decelerate bone losses
and diminish osteoporosis often described in these patients
[14]. Therefore, native GLP-2 and a dipeptidyl-peptidase
IV (DPP-IV) degradation-resistant gly-2 GLP-2 analog [7],
Teduglutide, have been evaluated in short-term, “proof of
concept” studies in the treatment of SBS patients [15,
16]. The positive eﬀects on intestinal morphology were2 Gastroenterology Research and Practice
conﬁrmed by increases in small intestinal villus heights and
crypt depths, and the positive absorptive eﬀects by increases
in the wet weight, and to a minor degree, in the energy
absorption. Positive eﬀects on bone mineral content were
also described [17]. However, the long-term eﬀects of GLP-2
treatment in SBS patients remain to be evaluated.
This open-label study describes the eﬀects of GLP-2,
400mcg oﬀered for subcutaneous injection TID, to eleven
patients for two consecutive years intermitted by an 8-week
washout period. As a part of the study design, parenteral
support was kept constant during the two years in order
to evaluate longitudinal changes in the intestinal absorption
and dietary intake in relation to GLP-2 treatment. Mucosal
morphology, renal function, body composition, bone min-
eral density and muscle function were also recorded.
2.MaterialandMethods
2.1. Patients. Eleven SBS patients (3 female, 8 male; 47 ± 11
years; remnant small bowel 157 ± 66cm; 2 with a colon;
7 had intestinal failure, 3 receiving parenteral ﬂuids and
electrolytes exclusively and 4 receiving parenteral nutrition;
4 had intestinal insuﬃciency and did not need parenteral
nutrition or ﬂuid) were recruited to the study based on a
fecal energy excretion exceeding 2.0MJ/d (measured at a
previous admission) or a remnant small bowel of 200cm or
less (measured perioperatively from the ligament of Treitz)
(Table 1). One patient had previously received native GLP-
2 (OBJ) and two teduglutide (LM and HRM) in the short-
term experiments, whereas the remaining 8 patients were
GLP-2 treatment na¨ ıve. All patients, except FL and LM, took
antidiarrhealmedication(codein,loperamideoropium)and
6 of eleven patients (HM, OB, EFP, JE, JHJ and UDJ) took
antisecretory agents (omeprazole).
2.2. Study Protocol. Over the two years, the patients were
admittedatleasteighttimestothehospitalfor72-hourseval-
uations (Table 2). After the baseline evaluations, the patients
were given native GLP-2, 400mcg TID, subcutaneous, for
one year. For these studies we employed synthetic human
GLP-2, as described previously [15]. During the ﬁrst year,
the patients were scheduled for readmissions at 13, 26 and
52 weeks (abbreviated Y1-W13, Y1-W26, Y1-W52, resp.,).
After the ﬁrst readmission at week 13, the patients were given
an option to test a double dose of GLP-2, 800mcg TID for
3 weeks. The patients, who accepted, were readmitted for
an extra 72-hour nutrient balance study at week 17 (Y1-
W17). After completing this evaluation, the original GLP-2
dose was reintroduced. GLP-2 treatment was discontinued
for 8 weeks after the ﬁrst 52 weeks of treatment. After a
72-hour washout evaluation, the GLP-2 treatment, 400mcg
TID, was reintroduced and evaluations were repeated during
admission at 13, 26 and 52 weeks during the second
year of treatment (abbreviated Y2-W13, Y2-W26, Y2-W52,
resp.,). In relation to the week 26 readmission, during the
second year of GLP-2 treatment, the patients were given
cholylsarcosine bile acid replacement therapy, 2 grams TID,
two days prior to the admission and during the 72-hour
balance studies [18, 19]. Cholylsarcosine was supplied as
the water soluble sodium salt, >99% pure by HPLC and
thin-layer chromatography, and was packed into gelatine
capsules (250 mg/capsule) [20]. Cholylsarcosine was taken
in relation to the three main meals and in conjunction with
subcutaneous GLP-2 injections.
2.2.1. Morphological Analysis. At least two small bowel
biopsy specimens were obtained before GLP-2 treatment at
baseline and repeated at week 52, year 1, in 6 of 7 patients
with a jejunostomy. Histologic sections of the biopsies were
analyzed by morphometric methods (Image pro plus) as
described previously [15].
2.2.2. Fluid, Electrolyte and Nutrient Balance Studies. The
study—and collection—period began at 9 o’clock on the
ﬁrst day of admission, where patients were requested to
urinate, defecate or empty their stoma-bags. During the
72-hour balance periods, all ad libitum oral intakeand
stomal output were weighed, and the contents of energy
(bombcalorimetry),carbohydrate(Englyst’smethod),nitro-
gen (Kjeldahl’s method), fat (gas liquid chromatography),
sodium and potassium (ﬂame photometry), calcium and
magnesium (atomic absorption spectrophotometry) were
determined as previously described [21, 22]. The absolute
intestinalabsorptionwascalculatedasthediﬀerencebetween
the ingested and excreted and the relative as the absolute
absorption divided by oral intake.
The medication and parenteral supplements were ﬁxed
according to the status at baseline.
2.2.3. Urine Creatinine Excretion and Creatinine Clearence.
Urinary creatinine was measured at 505nm as a pikrat-
creatinine complex using a standard hospital analytical
technique according to the method of Jaﬀe and the 72-hour
output calculated. The creatinine clearance was calculated
by diving daily urinary creatine excretion by the plasma
creatinine concentration.
2.2.4. Assessment of Body Weight, Body Composition and Bone
Mineral Density. The fasting body weights were measured
every morning after emptying of the bladder and stoma-
bags, before breakfast, using a leveled platform scale, and
were calculated as the mean for 4 consecutive days. Body
composition (BC) and bone mineral density (BMD) of the
posterior-anterior spine, hip and total body were measured
byDual-energyX-ray Absorptiometry (Norland XR-36 DXA
densitometer, Norland Corp., Fort Atkinson, WI., USA).
2.2.5. Biochemical Markers of Bone Turnover. Bone resorp-
tion was assessed from the concentration of s-CTX (Serum
CrossLabs one step ELISA; Nordic Bioscience, Denmark)
[23]. Bone formation was assessed from the concentration
of s-osteocalcin (Osteocalcin N-MID ELISA assay, Nordic
Bioscience, Denmark) [23].
2.2.6. Evaluation of Lung Function and Maximal Inspiratory
and Expiratory Force. Lung function was tested by dynamicGastroenterology Research and Practice 3
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and static spirometry and measurement of single-breath dif-
fusion capacity of carbon monoxide (MasterLab plethysmo-
graph, Jaeger, Germany) according to the recommendations
of the European Respiratory Society [24, 25]. Results were
expressed in absolute values and as percentage of predicted
values calculated according to European reference equations.
Respiratory muscle strength was assessed by measurement of
maximal expiratory and inspiratory pressures [26].
2.2.7. Evaluation of Maximal Aerobic ATP Turnover of Skeletal
Muscle Mitochondria. The 31P NMR spectroscopy investi-
gations were conducted in a short 26cm bore magnet at
2.9T as described previously [27–29]. The examination of
the forearm ﬂexor muscles and the tibialis anterior muscle of
the lower leg was done as two separate experiments on the
same day and both protocols involved: a 5 minutes rest, three
minutes of dynamic exercise at 50% of maximal voluntary
contraction followed by 10 minutes of recovery. The aim
of the measurements was to obtain from the pH and PCr
recovery a measure of the capacity of aerobic ATP synthesis.
On a separate day, patients performed an exercise test on
a modiﬁed Krogh cycling ergometer with the upper body in
a4 5 ◦ position [30]. Exercise was maintained at 60 round per
minute with an increase in workload by 50 Watt every third
minute until exhaustion. Breath-by-breath measurements
of pulmonary O2 consumption (VO2)w e r em a d ew i t ha n
onlinegasanalyzer(CPX/D,MedicalGraphics,St.Paul,MN)
and data were averaged every 30 seconds. Heart rate was
recorded noninvasively [31].
2.3. Ethics. The Ethics Committee for Medical Research
in Copenhagen, Denmark (KF 01-235/98) approved the
protocol. Procedures followed were in accordance with the
ethical standards of the Helsinki Declaration of 1975, as
revised in 1983. Patients signed informed consent before
entrance to the study.
2.4. Statistics. As the vast majority of data was normally
distributed, the results are presented as means ± standard
deviations. The diﬀerences between admissions periods were
tested with a Friedman repeated measures analysis of vari-
ance on ranks on using the SigmaStat for Windows Version
2.0 (1992–1995, Jandel Corporation, Erkrath, Germany) in
patients completing the study. For comparisons of admission
periods to the baseline period, the Dunnett method was used
as the post hoc test. A value of P<. 05 was considered
signiﬁcant.
3. Results
Results regarding compliance, safety, adverse events, quality
of life and treatment satisfaction are presented separately
[32]. In summary, all patients injected more than 93% of the
prescribed GLP-2. Three of eleven patients did not complete
the study. Two of these patients experienced abdominal pain,
and in one patient, the investigator discontinued GLP-2
treatment, since the feedback from the patient regarding the
administration of GLP-2 was lacking [32]. Abdominal pain
could be a consequence of providing an intestinotrophic
agent to patients with a relative stenosis, and caution should
probably be taken, when prescribing GLP-2 or analogs to
patients with a relative intestinal stenosis, a narrow stoma,
or a history of chronic abdominal pain [32].
3.1. Morphological Analysis. Villus height increased in 4 out
of 6 patients, but overall no signiﬁcant changes were seen
(316 ± 53µm versus 346 ± 87µm, P = .37) in relation to
GLP-2 treatment. Crypt depth increased in 3 patients, and
decreased in 3, but overall no change was seen (160 ± 63µm
versus 140 ±24µm, P = .44).
3.1.1.Fluid,ElectrolyteandNutrientBalanceStudies(Table 3).
Fecal wet weight was signiﬁcantly reduced by approximately
one liter/d at all time intervals after the initiation of GLP-
2 treatment (range 629 ± 862g/d to 1201 ± 1389g/d). The
average reduction the ﬁrst year was 811g/d and not diﬀerent
from the average reduction the second year of 1081g/d, and
no trend of a further increase in the eﬀect on fecal weight
beyond the 13th week of treatment was seen (Table 3). The
fecal wet weight excretion reverted to baseline levels in the
washout period after one year of treatment, but as for the
ﬁrst year the eﬀect on fecal weight was fully regained 13
weeks after treatment was reinstituted the second year. The
reduction in fecal wet weight was also seen in the two SBS
patients with colon-in-continuity and numerically equaled
the ﬁndings in the patients with a jejunostomy.
The reduction in fecal wet weight excretion was accom-
panied by a reduction in oral intake. However, in contrast
to the prompt eﬀect on fecal weight, the eﬀect on oral
intake gradually increased over the ﬁrst year by an average
from 449 ± 1061g/d after 13 weeks of treatment to 611 ±
813g/d after 26 weeks to ﬁnally 913 ± 996g/d after 52 weeks
(Y1-W52). Also in contrast to fecal excretions, oral intake
was not reversed to baseline values during the eight weeks
where treatment was stopped, but was only halved to an
intermediate level of 453 ± 641g/d. However, in the second
year the eﬀect on oral intake was already back to levels of
902 ± 919g/d after 13 weeks, comparable to eﬀects it took
52 weeks of treatment to reach the ﬁrst year. In the second
year, no further eﬀect was seen on oral intake beyond week
13, and the eﬀect leveled oﬀ at a decreased oral intake of
775 ± 886g/d and 1058 ± 1082g/d after 26 and 52 weeks of
treatment, respectively. The decrease in fecal output resulted
in a nearly comparable decrease in oral intake rendering
absolute eﬀect on intestinal absorption unaltered although
intestinal absorption in percentage of oral intake increased
(Table 3).
Similarly, the numerical increase in urine volume was
small and did not reach statistical signiﬁcance (on average
291g/d the ﬁrst year and 238g/d the second year) rendering
the overall urine excretion rather constant throughout the
GLP-2 treatment periods in spite of the reduced oral intake.
Fecal sodium excretions were reduced at all admissions (on
average 53mmol/day the ﬁrst year and 58mmol/day the
second year) in relation to GLP-2 treatment and reverted
to baseline levels during the washout period. Similarly,Gastroenterology Research and Practice 5
Table 2: Schedule of procedures and evaluations.
1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout (8 weeks post-treatment) Week 13 Week 26 Week 52
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2 GLP-2 +
Cholyl-sarcosine∗ GLP-2
Intestinal biopsy
(morphometry)
××
72-h balance on
diet, feces, urine
(wet weight, na+,
k+, mg2+, ca2+,
energy, fat,
carbohydrate,
protein)
×××× × × × ×
72-h Urinary
creatinine
excretion
×××× × × × ×
DEXA (body
weight + body
composition +
bone mineral
content)
×××× × × × ×
Vitamin D, PTH ×××× × × × ×
Bone resorption
and formation
markers(s-
crosslabs,
osteocalcin)
×××× ×
NMR scan ××
lung function + in-
and expiratory
force
××××
exercise test on
bike
××
∗Cholylsarcosine was given two days prior to the admission and during the 72-hour balance studies.
urinary sodium excretions increased at most admissions
(54mmol/day the ﬁrst year and 24mmol/day the second
year). Although the decrease in fecal excretion and the
increase in urinary excretion indicate that intestinal sodium
absorption must have been increased, the P-value for this
was not signiﬁcant (P-value of .06 from the data in Table 3).
Treatment did not aﬀect oral sodium intake in contrast to
oral wet weight intake.
Both dietary intake and fecal excretions of potassium
decreased with no signiﬁcant change in absorption although
urinary excretions increased during several sessions of
measurements. Consistent changes in dietary intake, fecal
excretion and intestinal absorption of calcium and magne-
sium were not seen. Urinary excretion of calcium did not
increase in relation to GLP-2 treatment (P = .08), whereas
urinary magnesium excretion increased signiﬁcantly (P =
.001) from a baseline of 2±2mmol/d to values ranging from
3 ±3mmol/d to 5 ±3mmol/d.
Theresultsontheenergyandmacronutrientbalancesare
presented in Table 4. On an average, treatment with GLP-2
numerically decreased oral energy intake by 349kJ/d in the
ﬁrst year and 1182kJ/d in the second year, which was less
than 3% and 8% of baseline intake and not signiﬁcant (P =
.69,Table 4).Fecalexcretionofenergynumericallydecreased
on an average by 448kJ/d in the ﬁrst year and 1438kJ/d
in the second year. None of these changes were signiﬁcant.
However, the combination of GLP-2 and cholylsarcosine
appeared successful in reducing fecal excretions by a total of
1852kJ/d (∼31%), which partly appeared to be caused by a
cholylsarcosine associated 42% decrease in fecal fat excretion
of 28g/d (1094kJ/d, P = .005), as GLP-2 alone did not
inﬂuence fecal fat (Table 4). Nevertheless, the accompanying
reduction in dietary intake reduced the overall gain in energy
absorption to a negligible amount of less than 100kJ/d
exceptfortheperiodwherecholylsarcosinewasadded,which
resulted in a numerical increase in absorption of 701kJ/day
or 8% of baseline, but still not enough to reach signiﬁcance.
Fecal excretions of carbohydrate and protein (nitrogen)
did not decrease (P = .08) with no demonstrable increase in
intestinal absorption (Table 4).6 Gastroenterology Research and Practice
Table 3: Diet, feces, absorption (diet-feces), and urine excretion of wet weight, sodium, potassium, calcium, and magnesium.
(mean ± SD, n = 8) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value∗
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2
GLP-2 +
Cholyl-
sarcosine#
GLP-2
W e tw e i g h t( g / d )
Diet 4680 ±1945 4232 ±1813 § 4069 ±1523 § 3768 ±1355 § 4228 ±1589 § 3779 ±1254 § 3905 ±
1293 §
3623 ±1047 § .03
Feces 2995 ±1905 2136 ±1388 § 2366 ±391 § 2048 ±1158 § 2759 ±1371 1853 ±1093 § 2094 ±
1139 §
1794 ±771 § <.001
Abs. absorption 1686 ±578 2096 ±600 1702 ±784 1720 ±506 1468 ±627 1926 ±854 1811 ±679 1929 ±656 .11
Rel. absorption 39 ±16 52 ±13 § 41 ±16 48 ±14 35 ±17 52 ±18 § 47 ±18 50 ±15 <.001
Urine 1407 ±860 1740 ±756 1720 ±749 1635 ±774 1410 ±807 1855 ±1002 1528 ±917 1551 ±596 .16
Sodium (mmol/d)
Diet 238 ±116 233 ±126 228 ±117 209 ±118 223 ±109 222 ±113 203 ±101 216 ±104 .41
Feces 264 ±132 197 ±113 § 234 ±96 § 203 ±96 § 250 ±150 198 ±108 § 226 ±119 § 195 ±79 § .001
Abs. absorption −26 ±84 36 ±64 −6 ±89 6 ±71 −27 ±126 25 ±74 −23 ±96 21 ±61 .06
Rel. absorption −24 ±72 13 ±29 −25 ±81 −18 ±74 −27 ±78 −8 ±92 −32 ±95 −2 ±55 .15
Urine 77 ±139 139 ±80 § 133 ±50 § 122 ±55 § 59 ±72 124 ±64 § 78 ±61 100 ±66 .001
Potassium (mmol/d)
Diet 117 ±45 107 ±43 § 111 ±38 § 100 ±43 § 104 ±43 § 93 ±34 § 90 ±26 § 90 ±24 § .007
Feces 49 ±41 32 ±31 § 31 ±28 § 28 ±24 § 46 ±30 24 ±21 § 26 ±23 § 23 ±22 § <.001
Abs. absorption 68 ±43 76 ±37 80 ±28 73 ±36 58 ±38 70 ±36 64 ±30 67 ±26 .21
Rel. absorption 58 ±24 72 ±28 74 ±19 § 72 ±24 56 ±30 73 ±28 72 ±25 75 ±22 § <.001
Urine 62 ±16 73 ±13 86 ±25 § 73 ±19 49 ±16 87 ±19 § 64 ±24 86 ±20 § <.001
Calcium (mmol/d)
Diet 49 ±30 44 ±27 42 ±20 34 ±20 § 39 ±28 § 32 ±19 § 31 ±18 § 32 ±20 § <.001
Feces 66 ±52 65 ±42 70 ±41 61 ±42 63 ±43 50 ±31 § 49 ±32 § 45 ±24 § <.001
Abs. absorption −17 ±35 −21 ±26 −28 ±27 §− 27 ±28 §− 25 ±25 §− 18 ±20 −18 ±26 −13 ±20 .009
Rel. absorption −39 ±59 −55 ±60 −72 ±63 −89 ±82 −87 ±76 −69 ±60 −77 ±112 −66 ±85 .24
Urine 3 ±33 ±34 ±44 ±44 ±45 ±4 5 ±4 4 ±3 .08
Magnesium (mmol/d)
Diet 19 ±81 8 ±81 9 ±71 7 ±7 § 18 ±71 6 ±6 § 16 ±5 § 15 ±4 § .03
Feces 32 ±27 31 ±32 34 ±33 33 ±35 34 ±30 29 ±27 28 ±25 30 ±29 .01
Abs. absorption −12 ±21 −12 ±25 −15 ±27 −16 ±28 −16 ±25 −13 ±23 −12 ±22 −15 ±26 .10
Rel. absorption −51 ±80 −42 ±89 −60 ±92 −67 ±99 −73 ±105 −61 ±108 −60 ±119 −79 ±128 .17
Urine 2 ±23 ±3 § 4 ±3 § 4 ±4 § 3 ±3 § 5 ±3 § 4 ±2 § 4 ±2 § .001
∗Friedman repeated measures analysis of variance on ranks in patients completing the study. For comparisons of admission periods to the baseline period,
the Dunnett method was used as the post hoc test. §∼P<. 05. #Cholylsarcosine was given two days prior to the admission and during the 72-hour balance
studies.
Sixoftheeightpatientscompletingthestudyoptedtotry
the double dose of GLP-2, 800mcg TID for 3 weeks and were
readmitted for an extra 72-hour nutrient balance study (Y1-
W17, Patients HRM, LM, GL, JE, JHJ and JV). Compared to
eﬀects at week 13, doubling the GLP-2 dose for three weeks
didnotsigniﬁcantlyaﬀectwetweightintake(4761±1780g/d
versus 4561 ± 1730g/d, P = .84), fecal wet weight excretion
(2469 ± 1468g/d versus 2484 ± 1678g/d, P = 1.00) or urine
wet weight excretion (1634 ± 857g/d versus 1752 ± 848g/d,
P = .18). Sodium, potassium, calcium and magnesium
balances were unaﬀected by the doubling of the GLP-2 dose.
Likewise, compared to eﬀects at week 13, doubling the GLP-
2 dose for three weeks did not signiﬁcantly aﬀect diet energy
intake(16123±5373kJ/dversus16178±6354,P = .56),fecal
energy excretion (6646 ± 3817kJ/d versus 6657 ± 4745kJ/d,
P = 1.00) or carbohydrate, fat or protein balances.
3.1.2. Urine Creatinine Excretion and Creatinine Clearance
(Table 5). On an average GLP-2 increased creatinine clear-
ance by 20mL/min or 28% in both years of treatment
(P = .04) from a baseline value of 73 ± 22mL/min (normal
range 48–150mL/min) to a range between 91 ± 14mL/min
and 97 ± 21mL/min during the ﬁrst year and a range
between 85 ± 36mL/min and 105 ± 23mL/min during the
second year. Creatinine clearence reverted to baseline levels
(67±43mL/min)duringthewashoutperiod.Corresponding
changes were seen in plasma and urine creatinine.
3.2. Assessment of Body Weight and Composition, Bone
Mineral Density, Biochemical Markers of Bone Turnover (S-
Crosslabs and S-Osteocalcin), Vitamin D and PTH (Table 6).
Althoughthe body weightnumericallyincreased from69.2±
9.1 at baseline to 72.6 ± 13.7 after two years of GLP-2Gastroenterology Research and Practice 7
Table 4: Diet, feces, and absorption (diet-feces) of energy, fat, carbohydrate, and protein.
(mean ± SD, n = 8) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value∗
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2
GLP-2 +
Cholyl-
sarcosine#
GLP-2
Energy (kJ/d)
Diet 14810 ±6429 14421 ±5556 14958 ±5485 14001 ±5445 15277 ±5926 13729 ±5369 13658 ±
4821
13494 ±4025 .69
Feces 5928 ±5305 5400 ±3968 5799 ±4095 5240 ±3668 6332 ±4197 4838 ±3469 4075±2866 4555 ±2596 .02
Abs. absorption 8882 ±3339 9021 ±2500 9159 ±2151 8761 ±2461 8945 ±2655 8892 ±2786 9583 ±2649 8940 ±2419 .82
Rel. absorption 64 ±18 66 ±16 64 ±13 65 ±12 61 ±16 66 ±15 72 ±12 67 ±14 .03
Fat (g/d)
Diet 103 ±43 113 ±44 114 ±46 103 ±40 109 ±46 104 ±44 98 ±45 103 ±42 .22
Feces 67 ±62 69 ±61 70 ±58 61 ±58 78 ±63 58 ±56 39 ±40 § 54 ±47 .005
Abs. absorption 36 ±35 44 ±25 44 ±20 42 ±33 31 ±29 46 ±28 59 ±26 48 ±24 .11
Rel. absorption 43 ±34 48 ±36 46 ±29 50 ±37 35 ±36 50 ±33 64 ±27 § 50 ±34 .002
Carbohydrate (g/d)
Diet 374 ±145 345 ±128 354 ±129 341 ±126 382 ±140 342 ±129 355 ±107 369 ±102 .62
Feces 66 ±60 57 ±43 59 ±40 57 ±37 70 ±42 52 ±33 50 ±31 51 ±19 .08
Abs. absorption 308 ±109 288 ±97 295 ±100 284 ±96 311 ±106 290 ±107 306 ±81 318 ±90 .53
Rel. absorption 84 ±98 4 ±68 4 ±58 4 ±58 3 ±68 5 ±5 87 ±4 86 ±3 .18
Protein (g/d)
Diet 105 ±51 101 ±48 107 ±44 96 ±52 115 ±54 99 ±41 95 ±39 102 ±41 .15
Feces 50 ±35 46 ±31 47 ±27 46 ±29 57 ±35 43 ±34 42 ±22 43 ±22 .08
Abs. absorption 55 ±36 54 ±31 60 ±25 49 ±33 58 ±33 56 ±29 53 ±33 59 ±32 .76
Rel. absorption 52 ±22 55 ±19 57 ±13 50 ±18 51 ±21 55 ±19 54 ±18 56 ±18 .50
∗Friedman repeated measures analysis of variance on ranks in patients completing the study. For comparisons of admission periods to the baseline period,
the Dunnett method was used as the post hoc test. §∼P<. 05. # Cholylsarcosine was given two days prior to the admission and during the 72-hour balance
studies.
Table 5: Plasma creatinine, urine creatinine, and creatinine clearence.
(mean ±
SD, n = 8)
1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value∗
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2
GLP-2 +
Cholyl-
sarcosine#
GLP-2
Plasma
Creatinine
(mmol/l)
0.103 ±0.019 0.097 ±0.019 § 0.096 ±0.019 § 0.095 ±0.020 § 0.094 ±0.023 § 0.088 ±0.018 § 0.101 ±
0.029 §
0.086 ±0.024 § .01
Urine
Creatinine
(mmol/d)
11 ±31 3 ±41 3 ±41 3 ±48 ±41 1 ±3 12 ±5 13 ±4 .016
Creatinine
Clearence
(mL/min)
73 ±22 91 ±14 § 97 ±21 § 93 ±28§ 67 ±43 90 ±26 § 85 ±36 § 105 ±23 § .04
∗Friedman repeated measures analysis of variance on ranks in patients completing the study. For comparisons of admission periods to the baseline period,
the Dunnett method was used as the post hoc test. §∼P<.05. #Cholylsarcosine was given two days prior to the admission and during the 72-hour balance
studies.
treatment,thisdidnotreachstatisticalsigniﬁcance(P = .25).
No signiﬁcant changes occurred regarding lean body mass
and fat mass, and bone mineral content was constant in
relation to the two years of GLP-2 treatment.
Signiﬁcant, but sporadic, diﬀerences between admission
periods were demonstrated regarding bone mineral density
of the femoral neck and the distal radius and ulna, but the
posthocanalyseswerenonsigniﬁcant.Nosigniﬁcantchanges
wereseenregardingz-scoresofthefemoralneckorthespine.
S-crosslabs decreased signiﬁcantly at week 13. Vitamin D
ﬂuctuations were probably related to the season of the year.
Osteocalcin and PTH remained constant throughout the two
years of GLP-2 treatment.
3.3. Evaluation of Physical Strength and Mitochondrial
Function of Skeletal Muscle (Lung Function and Maximal
Inspiratory and Expiratory Force, NMR Turnover Test and
Exercise Test). Measurements of lung function at baseline8 Gastroenterology Research and Practice
Table 6:Bodyweightandcomposition,bonemineraldensity,biochemicalmarkersofboneturnover(s-crosslabsands-osteocalcin),vitamin
Da n dP T H .
(mean ± SD) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value∗
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2
GLP-2 +
Cholyl-
sarcosine#
GLP-2
Body composition, kg
Body weight 69.2 ±9.17 0 .8 ±9.57 1 .2 ±9.77 0 .2 ±12.37 0 .2 ±14.07 1 .8 ±12.9 71.3 ±12.3 72.6 ±13.7 .25
Lean body mass 45.7 ±9.54 7 .3 ±9.34 7 .4 ±9.94 8 .0 ±10.04 6 .7 ±9.64 8 .0 ±10.0 47.1 ±9.9 46.9 ±10.3 .46
Fat mass 20.1 ±8.91 9 .4 ±8.82 0 .2 ±9.01 9 .3 ±8.82 0 .0 ±8.22 0 .7 ±8.9 20.7 ±8.6 21.8 ±8.7 .07
Bone mineral content 2.67 ±0.27 2.71 ±0.32 2.71 ±0.29 2.73 ±0.30 2.70 ±0.29 2.74 ±0.29 2.74 ±0.29 2.73 ±0.26 .75
Bone mineral density, g/cm2
Spine 0.97 ±0.25 0.96 ±0.26 0.97 ±0.26 0.95 ±0.24 0.95 ±0.24 0.95 ±0.22 0.96 ±0.23 0.96 ±0.22 .49
Femoral neck 0.79 ±0.14 0.80 ±0.16 0.79 ±0.14 0.78 ±0.14 0.78 ±0.13 0.76 ±0.13 0.78 ±0.12 0.77 ±0.14 .04
Dist. Rad+Uln 0.37 ±0.05 0.37 ±0.05 0.36 ±0.05 0.37 ±0.05 0.37 ±0.05 0.37 ±0.05 0.38 ±0.05 0.37 ±0.05 .02
Prox. Rad+Uln 0.77 ±0.06 0.77 ±0.07 0.77 ±0.06 0.78 ±0.06 0.78 ±0.07 0.78 ±0.06 0.78 ±0.06 0.78 ±0.07 .27
Prox. Rad 0.77 ±0.07 0.77 ±0.06 0.76 ±0.06 0.77 ±0.05 0.77 ±0.06 0.77 ±0.06 0.78 ±0.06 0.78 ±0.07 .06
Spine, Z-Score −0.70 ±1.78 −0.80 ±1.86 −0.71 ±1.89 −0.57 ±1.83 −0.82 ±1.81 −0.82 ±1.67 −0.83±1.70 −0.71 ±1.68 .37
Fem. Neck, Z-Score −0.85 ±1.10 −0.73 ±1.19 −0.84 ±1.04 −0.86 ±1.04 −0.85 ±1.11 −1.00 ±0.96 −0.85±0.94 −0.94 ±1.07 .23
S-Crosslabs, ng/mL 0.44 ±0.19 0.25 ±0.11 § 0.32 ±0.14 0.40 ±0.24 0.49 ±0.32 % % % .04
S-Osteocalcin, ng/L 24 ±12 24 ±10 21 ±92 5 ±15 24 ±16 % % % .75
P-PTH, pmol/L 4.5 ±3.24 .7 ±2.84 .3 ±2.05 .0 ±2.43 .8 ±1.74 .4 ±2.3 5.1 ±3.4 4.9 ±2.2 .92
P-Vitamin-D, nmol/L 79 ±28 57 ±25 55 ±31 91 ±49 78 ±37 87 ±52 89 ±63 92 ±44 .02
∗Friedman repeated measures analysis of variance on ranks in patients completing the study. For comparisons of admission periods to the baseline period,
the Dunnett method was used as the post hoc test. §∼ P<. 05. #Cholylsarcosine was given two days prior to the admission and during the 72-hour balance
studies.
showed that 7 of 8 (88%) patients had an obstructive
ventilatory defect. Five of 8 (63%) patients had a restrictive
ventilatory defect and 8 of 8 (100%) patients had decreased
diﬀusion capacity. No change was observed in relation to
the GLP-2 treatment in ﬂow indices as for example, FEV1,
static volumes as total lung capacity, residual volume and
vital capacity or diﬀusion capacity for carbon monoxide.
Yet, functional residual capacity decreased signiﬁcantly from
144 ± 23% at baseline to 128 ± 28% (P<. 001) at week
52. Respiratory muscle strength was within the normal limits
and did not change in relation to the GLP-2 treatment.
Theintensionofthe 31PNMRspectroscopicexperiments
was to test, if the capacity of aerobic ATP synthesis of the
skeletal muscle was changed by the GLP-2 treatment. The
measurements were performed in two muscle groups, the
tibialis anterior, which is primarily a red muscle (type 1) [29]
and the forearm ﬂexor muscle, which is primarily of type 2
[33]. Table 7 shows the results at baseline before treatment
was initiated. The diﬀerences observed between the two
muscles are similar to what has been observed previously
[29]. The data from the subsequent measurements at week
13 is not shown, since no signiﬁcant changes were observed
in any of the parameters recorded.
In relation to the exercise test, the resting heart rate and
VO2 were 78 ± 4bpm and 0.3 ± 0.05L/min, at baseline,
respectively, and when patients were exhausted during
cycling the heart rate and VO2 increased to 161 ±5bpmand
1.8 ± 0.9L/min, respectively, (P<. 05). Thirteen weeks of
treatment with GLP-2 did not change resting and exercise
heart rate and VO2.
4. Discussion
In contrast to the previous short-term studies, where active
eﬀorts were made to enforce strict compliance to injections
andadhesiontoﬁxeddietsinhospital-likesettings,thisstudy
aimed at describing the consequences of introducing and
expanding long-term GLP-2 treatment to the daily life of
the short bowel patients. However, parenteral support was
deliberately maintained constant. GLP-2 was well tolerated
as demonstrated by the high compliance in the SBS patients
completing this study (≥94%) but also in the patients
discontinuing GLP-2 treatment (≥93%).
The eﬀect of long-term GLP-2 treatment on intestinal
morphology was evaluated in biopsies taken at baseline
and after a year of GLP-2 treatment in six patients with
a jejunostomy. No signiﬁcant changes in the villus height
(10 ±25%, P = .37) or the crypt depth (−5 ±28%, P = .44)
were observed. This was in accordance with the ﬁndings in
the initial 35 days GLP-2 study [15], where 400µgo fn a t i v e
GLP-2 was given subcutaneously twice daily (corresponding
to 0.013 ± 0.002 mg/kg/d, a range of 0.011–0.017 mg/kg/d).
N oc h a n g e sw e r es e e ni nv i l l u sh e i g h t( 1 0± 19%, P = .14)
or the crypt depth (18 ± 42%, P = 0.28). In contrast,
21 days of teduglutide in doses ranging from 0.03 to 0.10
mg/kg/d [16] increased villus heights by 38±45% (P = .030)
and crypt depth increased 22 ± 18% (P = .010) in eight
short bowel jejunostomy patients. The more pronounced
positive eﬀects of teduglutide may be due to the prolonged
half-life of the peptide and subsequently by the larger area
under the curve, or simply be related to the larger dosesGastroenterology Research and Practice 9
Table 7: 31PMRS measurements on primarily red (tibialis anterior) or white (forearm) skeletal muscle of subjects before treatment with
GLP2. Tibialis anterior represents a primarily “red” and the forearm ﬂexor group a primarily “white” muscle. The ﬁrst 4 lines are recorded
at rest where PCr is given as mM. The subsequent 4 lines are recorded after a 1 min of maximal contraction. The PCr and pH change is the
diﬀerence between the resting value and the value measured by the end of exercise. The T0.5 values are half times for recovery (s), assuming
monoexponential recovery after exercise (27).
Forearm Flexors Tibialis Anterior
At rest:
PCr 24.3 ± 1.7 23.5 ± 2.3
PCr/ATP 4.2 ± 0.5 4.3 ± 0.4
PCr/Pi 7.7 ± 1.9 6.0 ± 1.5∗
pH 7.04 ± 0.04 6.99 ± 0.05∗∗
After exercise:
PCr change 14.0 ± 3.3 13.7 ± 5.7
pH change 0.46 ± 0.29 0.18 ± 0.17∗
T “0.5 PCr” 59.6 ± 16.0 45.1 ± 11.0
T “0.5 Pi” 34.8 ± 12.0+ 26.7 ± 7.0+
V “max”0 . 2 5 ± 0.08 0.27 ± 0.19
∗P<. 05 and ∗∗P<. 01 for arm versus leg. +P<. 05 for T0.5 PCr versus T0.5 Pi.
used in that study. The ﬁnding of continuously elevated
endogenous GLP-2 levels and increased mucosal growth in
short bowel patients with colon-in continuity and in obese
patients subjected to jejunoileal bypass operations supports
the “area under the curve” theory. In these patients, the
endogenous meal-stimulated peak-concentrations of GLP-2
are much lower than the pharmacologically induced peaks,
but a continuous endogenous GLP-2 secretion occurs, even
after a night of fasting. Thus, the increases in villus height
and crypt depths in short bowel patients with a jejunostomy
treated with either native GLP-2 or teduglutide is still
signiﬁcantly less than the 80% increases in villus height
demonstrated in patients with jejunoileal bypass operations
[34] and the 2–300% increases in villus heights described
in patients with enteroglucagonomas [35, 36]. However, it
is important to notice that local concentrations of GLP-
2 delivered by paracrine secretions may not reﬂect plasma
levels.
The magnitude of the eﬀects of GLP-2 and teduglutide
on bowel morphology is important in the discussion of
the potential for cancerous growth attributable to these
p e p t i d e s .G L P - 2 ,a n dt oag r e a t e rd e g r e e ,t e d u g l u t i d e ,h a v e
been shown to promote an increase in the growth of mucosal
neoplasms in mice developing colonic tumors in response
to the methylating carcinogen 1,2-dimethylhydralazine [37].
Despite the fact that the small bowel is the longest region of
the alimentary tract, neoplasms of the small bowel are very
uncommon. Therefore, in our practice, screening for small
bowelneoplasmsisnotconsideredpriortoinitiationofGLP-
2 treatment or during treatment. On the other hand, cancer
of the colon and rectum is the fourth most common newly
diagnosed cancer in The United States and Europe. The col-
orectal adenomas that may predispose to this condition are
even more frequent. It could be argued, that screening prior
to the initiation of GLP-2 treatment would be appropriate
in short bowel patients with a preserved colon. However, as
stated, the patients, who have undergone jejono-ileal bypass
operations, have continuously elevated endogenous GLP-
2 plasma concentrations. In these patients, the changes in
the functional remnant jejunum clearly supersede changes
obtained by pharmacological intervention, and the colonic
crypts are also more enlarged. Thus, it is suggested, that
there is no indication for regular colonoscopic surveillance.
Although it will probably take another 10–20 years to
establish whether jejuno-ileal bypass is associated with an
increased risk of large bowel cancer in humans, the ﬁndings,
so far, are negative [38]. The colon was normal before and
after GLP-2 treatment in the two SBS patients with colon-in
continuity in this study.
Theeﬀectsonchangesinintestinalabsorptioninrelation
to GLP-2 treatment were evaluated in balance studies.
Signiﬁcant, clinically relevant and reproducible eﬀects could
be demonstrated on intestinal wet weight excretion and
absorption over the two years of GLP-2 treatment. GLP-2,
400mcg/d TID (corresponding to 0.018 ± 0.002 mg/kg/d,
range 0.014–0.020 mg/d), reduced the fecal wet weight
excretion from baseline values of approximately 3.0 to
approximately2.0kg/daftertheﬁrstyearofGLP-2treatment
areduction ofthe same magnitude wasdemonstrated during
the second year. This reduction in the fecal wet weight
excretion exceed the eﬀects described in the initial 35 days
GLP-2 study (400mcg BID corresponding to 0.013 ± 0.002
mg/kg/d, range 0.011–0.017mg/kg/d), where the fecal wet
weightdecreasedfrom3.2kg/dto2.8kg/d,andinthe21days
teduglutide study (doses ranging from 0.03 to 0.15mg/kg/d
OD), where fecal wet weight decreased from 2.8 to 2.1 kg/d.
However, in these studies the oral intakes were maintained
constant as a part of the protocol.
In this study, the fecal wet weight excretion was not
reduced by doubling the GLP-2 dose in six patients in this
study for 3 weeks. Thus, the maximal eﬀect may have been
reached by the TID injection regimen.
The decrease in fecal wet weight excretion was gradually
accompanied by a decline in the oral wet weight intake,10 Gastroenterology Research and Practice
therebymaintainingtheintestinalwetweightabsorptionand
urinary weight constant. In this study, parenteral support
was kept constant during the entire study unless otherwise
indicated by the patient and the investigator, and it was
deliberately kept constant during the balance periods. An
alternative approach would have been to taper the parenteral
support according to the urinary production keeping the
hyperphagic intake constant.
Since, the oral intake did not increase, and since the
parenteral supplement of ﬂuid and electrolytes was kept con-
stant, the signiﬁcant increases in urinary sodium, potassium
and magnesium and the borderline signiﬁcant increase in
the urinary calcium excretion reﬂect the beneﬁcial eﬀects
of GLP-2 on the intestinal absorption of these electrolytes.
Although urinary volume did not increase signiﬁcantly in
relation to GLP-2 treatment, the renal function, evaluated by
the renal creatinine clearance, improved signiﬁcantly in this
study. Renal impairment is a documented complication in
HPN patients and is at least partially due to a relative chronic
dehydration [39]. Since parenteral support is frequently
administered during nighttime, many short bowel patients
experience relative over-hydration during nighttime and
relativedehydrationduringdaytime.Wespeculate,thatGLP-
2 treatment reduces the amplitude of the daily ﬂuctuations
in the ﬂuid-balance of the short bowel patients, thereby
reducing the daily interval, when dehydration is present. The
positive eﬀects on renal function are also reﬂected in the
decrease in plasma-creatinine and the increase in plasma-
CO2-total in relation to GLP-2 treatment.
Although, the fecal energy excretion tended to decrease
in relation to long-term GLP-2 treatment, this did not aﬀect
the overall intestinal energy absorption, since the dietary
energy intake tended to decrease accordingly. In the short-
term studies employing native GLP-2 and teduglutide, the
dietary intakes were ﬁxed, and this may explain the positive
trend towards an increase in the overall energy absorption.
In the short-term study with native GLP-2, the absolute
energyabsorptiontendedtoincreasebyapproximately400±
600kJ/d (∼100 kcal/d; P = .09). In the study using the
dipeptidyl peptidase IV-resistant GLP-2 analog teduglutide,
in doses 0.03 to 0.15 mg/kg/d, in 16 short-bowel patients
(six with remnant parts of the colon), fecal energy excretion
was reduced by approximately 800kJ/d (P = .04), but
this only translated into a signiﬁcant increase in intestinal
absorption of approximately 1000kJ/d in a post hoc deﬁned
subset of patients with high dietary compliance during
balance studies. In none of these three studies signiﬁcant
changes in the absorption of individual macronutrients
were demonstrated. Although, a type-2 error is likely, the
combination of GLP-2 and cholylsarcosine only tended to
increase the fat absorption (36 ± 35g/d versus 59 ± 26g/d,
P = .08). However, all the patients receiving 2 grams of
cholylsarcisine TID (8 capsules TID) responded, that they
would not be able to continue this treatment long-term, and
the clinical applicability therefore seems limited.
Originally, we believed that the marginal eﬀects on
intestinal energy absorption in the initial 35-days native
GLP-2 study could explain the rather dramatic changes seen
in body weight and body composition [15]. In the light of
the negative ﬁndings on intestinal energy absorption, body
weight and body composition in this long-term GLP-2 study,
the increases described in body weight, lean body mass and
theconcurrentreductioninfatmassintheinitialnativeGLP-
2 study could simply reﬂect a transient ﬂuid retention in the
initial phase of GLP-2 treatment prior to an adjustment to
the new equilibrium.
In contrast to the initial native GLP-2 study, no changes
were observed regarding bone mineral content in relation
to long-term GLP-2 treatment. Again, acute ﬂuctuations
in calcium absorption or changes in bone formation and
resorption could account for these conﬂicting ﬁndings.
The GLP-2 dose currently suggested in the treatment of
osteoporosis is 1600µg given at bedtime. Thus, the lower
dose and the timing of injections may also explain the
lack of eﬀect of GLP-2 on bone mineral density in this
study. In the initial study by Haderslev et al., positive
eﬀects on urinary excretions of markers of bone resorption,
deoxypyridinoline and pyridioline, were described [17].
However, to compensate for day-to-day variation in urinary
volume, these data were corrected for urinary creatinine
excretion on the assumption that for each patient the 24-
hour urinary creatinine excretion was constant. However,
since GLP-2 seems to aﬀect urinary creatinine excretion
by other means, the interpretation of these results may be
incorrect. Thus, the clinical role of GLP-2 in the treatment of
osteoporosis remains uncertain. It is currently investigated
in postmenopausal women in a long-term, double blind,
placebocontrolledtrial,andstudiesonthephysiologicalbasis
of the suggested eﬀect of GLP-2 on bone resorption and
formation are ongoing.
Since GLP-2 was initially believed to improve nutritional
status in short bowel patients, we included measures of
physical function in this study, including 31P NMRS testing
maximal aerobic ATP turn-over of red and white skeletal
muscle. In accordance with the negative ﬁndings on body
composition, none of these measures improved in relation
to long-term GLP-2 treatment.
In conclusion, the main eﬀect of GLP-2 treatment in
patients with short bowel syndrome, where the parenteral
support is kept constant, is a reduction in fecal losses of ﬂuid
and electrolytes. The eﬀects on energy and macronutrient
absorption are minor. This enables the patients to maintain
their intestinal ﬂuid and electrolyte absorption at lower oral
intakes. A reduction in the amplitude in the ﬂuctuations of
the daily ﬂuid-balance in relation to GLP-2 treatment may
explain the beneﬁcial eﬀects on renal function.
An alternative approach to beneﬁt from the positive
eﬀects of GLP-2 on intestinal absorption is to wean the SBS
patients from parenteral support by encouraging them to
maintain a hyperphagic oral intake during GLP-2 treatment.
If the need for parenteral ﬂuid support could be reduced
by the magnitude of the reduction in fecal wet weight
excretions, that is, approximately 1000g/d, theoretically
approximately 10–15% of short bowel patients with intesti-
nalfailure(basedonevaluationsoftheHPNvolumesneeded
intheDanishHPN-cohort)wouldbeabletoregainintestinal
autonomy, and be weaned from HPN. They could have their
central line removed in relation to treatment with GLP-2.Gastroenterology Research and Practice 11
It must, however, be emphasized, that all current data is
obtained in open, nonrandomized studies and should be
regarded as preliminary. However, the weaning strategy is
currently tested in double blind, placebo-controlled trial.
Although the preliminary results are inconsistent, it is
likely that GLP-2 or analogs eventually could contribute to
the limited treatments armamentarium of the short bowel
syndrome.
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